Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02291 心泰醫療
Listing Date2022/11/08
Listing Price29.150
  • 27.200 -0.650 (-2.334%)    Sink Below Listing Price
  • 15-min delayed, last update: 30/03/2023 17:59
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    1 lot
  • One Lot Success Rate

LEPU Scientech Medical Technology (Shanghai) founded in 1994, it have been dedicated to the research, development, manufacture and commercialization of interventional medical devices primarily targeting structural heart diseases. It is a leading interventional medical device provider in China for congenital heart diseases (“CHD”), with a market share of 38% in terms of revenue recognized for the sales in China in 2021. It is the largest manufacturer of CHD occluder products and the related procedural accessories in China.

The Group had a comprehensive product portfolio of 20 marketed occluder products and nine occluder product candidates as well as 21 major heart valve product candidates. All of products are developed in-house. It includes primarily various CHD occluder products and PFO occluder products and LAA occluder products for prevention of cardioembolic stroke and related symptoms, including migraine, peripheral arterial embolism, and decompression sickness.

The Group has established research and development centers in Beijing and Shanghai.

It also had an expansive collection of intellectual property rights including 232 registered patents and 51 pending patent applications in China as well as 14 patents under application in the United States and the European Union.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot1000
No. of Offer Shares22.46M H shares
No. of International Offer Shares20.21M H shares
No. of HK Offer Shares2.25M H shares
Offer Price$29.15 - $31.45
Stock Code2291
Sponsor(s)China International Capital Corporation Hong Kong Securities Limited
Underwriter(s)China International Capital Corporation Hong Kong Securities Limited, CLSA Limited, China Galaxy International Securities (Hong Kong) Co., Limited, Huatai Financial Holdings (Hong Kong) Limited, Valuable Capital Limited
Application PeriodOct 27 (Thu) - noon, Nov 01 (Tue)
Price Determination DateNov 01 (Tue)
Result Announcement DateOn or before Nov 07 (Mon)
Result Announcement DateOn or before Nov 07 (Mon)
Dealings in Shares commence onNov 08, 2022. (Tue)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$29.15 - $31.45
Capitalization (H Shares)10.11B - 10.91B
NAV / share ($)$4.71 - $4.86 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 30.30, the net proceeds raised would be HKD 592.10M, of which
50.7% : Fund research and development activities
24.3% : Sales and marketing activities
5% : Expand production capacity and strengthen manufacturing capabilities
10% : Fund potential strategic investments and acquisitions
10% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.